$ICPT Company News This shocking strategy will save your

New Post Public Reply Private Reply Replies (0) Message Board

Jan 17, 2014 at 11:04 AM

$ICPT Company News

This shocking strategy will save your portfolio 6:01 a.m. Jan. 15, 2014 - Jeff Reeves
Alnylam shares settle down after 40% gain; analysts are skeptical 1:16 p.m. Jan. 14, 2014 - Russ Britt
Intercept, Intuitive take diverging paths on the market roller coaster 10:51 a.m. Jan. 14, 2014 - Russ Britt
Dow industrials suffer worst drop since Sept. 20: Stock market live blog recap 4:41 p.m. Jan. 13, 2014 - blogs.marketwatch.com
Beam up on Suntory deal; Elliott report lifts Juniper 4:18 p.m. Jan. 13, 2014 - Sue Chang
Merck shares hit 52-week high on drug hopes, plans for cutbacks 12:31 p.m. Jan. 13, 2014 - Russ Britt
Intercept, Lululemon, SodaStream shares slump 10:22 a.m. Jan. 13, 2014 - Saumya Vaishampayan
S&P 500 gains for week; builder stocks rally as yields fall; the wonder of liver-drug stocks (live blog recap) 10:15 a.m. Jan. 13, 2014 - blogs.marketwatch.com
Clovis Oncology, seen as 'next ICPT,' jumps 5% 9:47 a.m. Jan. 13, 2014 - Victor Reklaitis
Intercept shares trip short-sale circuit breaker 9:32 a.m. Jan. 13, 2014 - Laura Mandaro
Intercept, Celgene on move amid J.P. Morgan event 9:20 a.m. Jan. 13, 2014 - Victor Reklaitis
Banks, hedge funds and what Citi has to tell its rich clients 7:47 a.m. Jan. 13, 2014 - Shawn Langlois
Alcoa tops S&P losers, Twitter extends losing streak 4:29 p.m. Jan. 10, 2014 - Sue Chang
Macy’s up on restructuring; Apple and Samsung to talk 4:40 p.m. Jan. 9, 2014 - Sue Chang
Stock record? Intercept Pharma up nearly 300% on drug test results 2:14 p.m. Jan. 9, 2014 - Russ Britt
Intercept Pharma, Kythera take off in IPOs 10:53 a.m. Oct. 11, 2012 - MarketWatch.com
Intercept Pharma, Kythera take off in IPOs 10:34 a.m. Oct. 11, 2012 - MarketWatch.com
In the IPO desert, Thursday brings rain 9:42 a.m. Oct. 11, 2012 - MarketWatch
Intercept Pharma 5M-share IPO prices at high end 7:06 a.m. Oct. 11, 2012 - MarketWatch.com
Stocks to watch Thursday: Ruby Tuesday, Realogy 5:44 a.m. Oct. 11, 2012 - MarketWatch

5 Dumbest Things on Wall Street This Week 7:00 a.m. Today - TheStreet.com
3 Critical Factors For Intercept Bulls Now 4:02 a.m. Jan. 16, 2014 - Seeking Alpha
Athersys: Why Did Shareholders Come Knocking At The Door Once Again? 3:15 p.m. Jan. 15, 2014 - Seeking Alpha
Intercept Pharma cools off after presentation 11:04 a.m. Jan. 15, 2014 - Seeking Alpha
Today's Dead Cat Bounce Stock Is Intercept Pharmaceuticals (ICPT) 9:45 a.m. Jan. 15, 2014 - TheStreet.com
Intercept rallies ahead of conference, BofA defends lofty target 8:29 a.m. Jan. 15, 2014 - Seeking Alpha
Hot New Biotech Knows Roller-Coaster Feeling 7:49 p.m. Jan. 14, 2014 - WSJ.com
Intercept Pharmaceuticals Inc (ICPT): Today's Featured Drugs Laggard 5:01 p.m. Jan. 14, 2014 - TheStreet.com
Intercept Pharma falls again as article strikes cautious tone 11:07 a.m. Jan. 14, 2014 - Seeking Alpha
The Short Story Of Intercept Pharmaceuticals (Part I): A Conference Call With Expert Physicians 10:20 a.m. Jan. 14, 2014 - Seeking Alpha
ICPT: Time to Catch a Rising Star With Intercept Stock? 8:34 a.m. Jan. 14, 2014 - InvestorPlace.com
SA PRO: Top Long And Short Ideas, Monday January 13 7:30 a.m. Jan. 14, 2014 - Seeking Alpha
'Fast Money' Recap: The Economy and the Market 5:00 a.m. Jan. 14, 2014 - TheStreet.com
XBI – Be Careful With This Biotech ETF After Its Violent Breakout 3:00 a.m. Jan. 14, 2014 - InvestorPlace.com
Biotech Stocks Back On Top, Led By Biogen, Alexion 5:07 p.m. Jan. 13, 2014 - Investors Business Daily
Watch Out for Mr. Downside 4:18 p.m. Jan. 13, 2014 - RealMoney.com
Weak Action Threatens to Spread 1:10 p.m. Jan. 13, 2014 - RealMoney.com
Summer Street shrugs off Intercept Pharma LDL concerns 11:58 a.m. Jan. 13, 2014 - Seeking Alpha
A Sleepy Start to the Week 10:56 a.m. Jan. 13, 2014 - RealMoney.com
Good News Continues to Roll in for CytRx 9:59 a.m. Jan. 13, 2014 - Wall St. Cheat Sheet

Harwood Feffer LLP Announces Investigation of Intercept Pharmaceuticals, Inc. 8:00 p.m. Jan. 15, 2014 - PR Newswire - PRF
Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Intercept Pharmaceuticals, Inc. 2:03 p.m. Jan. 14, 2014 - BusinessWire - BZX
Small Cap Buzz: GW Pharmaceuticals, Intercept Pharmaceuticals, Medbox Inc, GreenGro Technologies 11:19 a.m. Jan. 13, 2014 - ACCESSWIRE
Intercept Reports Additional Details About FLINT Trial Provided by NIDDK 6:06 p.m. Jan. 12, 2014 - GlobeNewswire
Intercept to Present at the J.P. Morgan Healthcare Conference 6:31 p.m. Jan. 10, 2014 - GlobeNewswire
Intercept Provides 2013 Year-End Update and 2014 Anticipated Milestones 4:05 p.m. Jan. 9, 2014 - GlobeNewswire
Intercept Provides 2013 Year-End Update and 2014 Anticipated Milestones 4:05 p.m. Jan. 9, 2014 - GlobeNewswire
Intercept Announces NASH Primary Endpoint Met: FLINT Trial Stopped Early for Efficacy Based on Highly Statistically Significant Improvement in Liver Histology 7:33 a.m. Jan. 9, 2014 - GlobeNewswire
Intercept Pharmaceuticals to Provide 2013 Update on Clinical Programs for Obeticholic Acid on January 9 4:05 p.m. Jan. 2, 2014 - GlobeNewswire
Healthcare Companies Report Interim Data, Clinical Study Results, and Announcements - Research Report on Pfizer, Coronado Biosciences, Spectranetics, Celsion, and Intercept 8:00 a.m. Dec. 18, 2013 - PR Newswire
INTERCEPT PHARMACEUTICALS, INC. SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Intercept Pharmaceuticals, Inc. Regarding Possible Breaches of Fiduciary Duty 6:31 p.m. Dec. 9, 2013 - PR Newswire
Financial Results, Agreements, Meetings, and Clinical Trials - Research Report on Cell Therapeutics, Akorn, Ligand, Intercept Pharmaceuticals and Ariad Pharmaceuticals 8:00 a.m. Nov. 20, 2013 - PR Newswire
Intercept Pharmaceuticals Reports Third Quarter 2013 Financial Results 6:05 a.m. Nov. 14, 2013 - PR Newswire
Trial Results Presentations, Public Offerings, Acquisitions and Extension Study Results - Research Report on Medtronic, Steris, Intercept, Wright, and Synageva 7:00 a.m. Oct. 23, 2013 - PR Newswire
Intercept Announces Pricing of Public Offering of Common Stock By Selling Stockholders 8:02 p.m. Oct. 8, 2013 - PR Newswire
Keryx Biopharmaceuticals, Inc. Announces Appointment of Daniel P. Regan to Board of Directors 7:30 a.m. Oct. 4, 2013 - GlobeNewswire
Business Strategy, Partnerships, Presentation, and Appointment - Research Report on Merck, GSK, Sanofi, Intercept, and KYTHERA 7:00 a.m. Oct. 4, 2013 - PR Newswire
Additional Results of Global Primary Biliary Cirrhosis Study Group Analysis to be Presented at AASLD Annual Meeting 3:05 p.m. Oct. 1, 2013 - PR Newswire
Intercept Pharmaceuticals Reports Second Quarter 2013 Financial Results 5:00 a.m. Aug. 13, 2013 - PR Newswire
Intercept Pharmaceuticals to Present at the Wedbush Securities Life Sciences Management Access Conference 5:00 a.m. Aug. 5, 2013 - PR Newswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...